ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Patrick Vallance, GlaxoSmithKline’s president of R&D, will leave the British drug giant in March 2018 to become the U.K. government’s chief scientific adviser. To fill his spot, GSK has recruited Hal Barron, current president of R&D at Calico, the secretive aging biology firm funded by Alphabet, Google’s parent company. Barron was previously chief medical officer at Roche. He will remain in San Francisco to boost GSK’s R&D business development in the city.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter